Seres Therapeutics, Inc.MCRBNASDAQ
Loading
Year-over-year operating cash flow growth rate
Percentile
P0
Near historical low
vs 5Y Ago
-25x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -766.82% |
| Q3 2025 | 116.60% |
| Q2 2025 | -149.38% |
| Q1 2025 | 169.21% |
| Q4 2024 | -12.12% |
| Q3 2024 | 12.89% |
| Q2 2024 | -12.98% |
| Q1 2024 | 25.82% |
| Q4 2023 | 19.84% |
| Q3 2023 | -189.80% |
| Q2 2023 | 186.16% |
| Q1 2023 | -44.79% |
| Q4 2022 | 11.23% |
| Q3 2022 | -19.41% |
| Q2 2022 | 24.90% |
| Q1 2022 | -28.12% |
| Q4 2021 | -140.60% |
| Q3 2021 | 421.81% |
| Q2 2021 | -34.58% |
| Q1 2021 | -64.53% |
| Q4 2020 | 30.69% |
| Q3 2020 | -1.17% |
| Q2 2020 | -5.42% |
| Q1 2020 | -67.57% |
| Q4 2019 | 20.88% |
| Q3 2019 | -55.17% |
| Q2 2019 | 63.61% |
| Q1 2019 | -355.75% |
| Q4 2018 | 154.87% |
| Q3 2018 | 10.09% |
| Q2 2018 | 4.07% |
| Q1 2018 | -29.87% |
| Q4 2017 | -470.86% |
| Q3 2017 | 85.93% |
| Q2 2017 | -0.03% |
| Q1 2017 | -23.28% |
| Q4 2016 | -83.03% |
| Q3 2016 | 55.11% |
| Q2 2016 | -124.97% |
| Q1 2016 | 976.61% |